Congress

Cost-effectiveness of Bezlotoxumab for the prevention of recurrence of clostridium difficile infection in high risk patients in Spain


Skip to content
Privacy Summary

This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.